| Literature DB >> 24615125 |
Nicholas S Geraci, Rami M Mukbel, Michael T Kemp, Mariha N Wadsworth, Emil Lesho, Gwen M Stayback, Matthew M Champion, Megan A Bernard, Mahmoud Abo-Shehada, Iliano V Coutinho-Abreu, Marcelo Ramalho-Ortigão, Hanafi A Hanafi, Emadeldin Y Fawaz, Shabaan S El-Hossary, Glenn Wortmann, David F Hoel, Mary Ann McDowell.
Abstract
Phlebotomus papatasi sand flies are among the primary vectors of Leishmania major parasites from Morocco to the Indian subcontinent and from southern Europe to central and eastern Africa. Antibody-based immunity to sand fly salivary gland proteins in human populations remains a complex contextual problem that is not yet fully understood. We profiled the immunoreactivities of plasma antibodies to sand fly salivary gland sonicates (SGSs) from 229 human blood donors residing in different regions of sand fly endemicity throughout Jordan and Egypt as well as 69 US military personnel, who were differentially exposed to P. papatasi bites and L. major infections in Iraq. Compared with plasma from control region donors, antibodies were significantly immunoreactive to five salivary proteins (12, 26, 30, 38, and 44 kDa) among Jordanian and Egyptian donors, with immunoglobulin G4 being the dominant anti-SGS isotype. US personnel were significantly immunoreactive to only two salivary proteins (38 and 14 kDa). Using k-means clustering, donors were segregated into four clusters distinguished by unique immunoreactivity profiles to varying combinations of the significantly immunogenic salivary proteins. SGS-induced cellular proliferation was diminished among donors residing in sand fly-endemic regions. These data provide a clearer picture of human immune responses to sand fly vector salivary constituents.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24615125 PMCID: PMC4015589 DOI: 10.4269/ajtmh.13-0130
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Summary of human peripheral blood donors
| Abbreviation | Country | Number of blood donors | |||
|---|---|---|---|---|---|
| MENA sites | |||||
| Cairo | CA | Egypt | − | − | 37 |
| Aswan | AW | Egypt | + | − | 40 |
| North Sinai | NS | Egypt | + | + | 34 |
| Amman | AM | Jordan | − | − | 37 |
| Malka | MA | Jordan | + | − | 41 |
| Swaymeh | SW | Jordan | + | + | 40 |
| US military | |||||
| Control | United States | − | − | 29 | |
| Bitten | United States | + | − | 17 | |
| Infected | United States | + | + | 23 | |
Marks indicate the presence (+) or absence (−) of endemic P. papatasi populations and known cases of active L. major transmission in the region.
MENA locations in which human peripheral blood donors resided.
The condition of US military personnel stationed in the United States (control) or deployed in Iraq (bitten and infected) during 2007.
Marks indicate yes (+) or no (−) as to whether US military personnel reported exposure to sand fly bites or there was a confirmed diagnosis of cutaneous leishmaniasis while deployed in Iraq.
Figure 1.Characterization of whole P. papatasi salivary gland protein extract sonicates and human host antibody reactions. (A) Immunoblot examples of plasma donors from three regions in Egypt and differentially exposed US military personnel with antibody specificity to P. papatasi salivary proteins. Lanes are designated by regional plasma donor codes (CA, AW, and NS) or differential exposure codes (Con = Control, Bit = Bitten, and Inf = Infected). (B) Comparison of immunoblot example and whole P. papatasi salivary gland protein sonicate. Lane 2 displays an immunoblot image of a North Sinai plasma donor with broad antibody specificities to P. papatasi salivary gland proteins. Lane 3 displays a Coomassie Brilliant Blue R-250-stained P. papatasi whole-salivary gland protein sonicate run on a denaturing SDS-PAGE gel. Lanes 1 and 4 are PageRuler protein MW ladders (Fermentas).
Characteristics of salivary proteins with significant differences in host antibody specificity profiles
| Salivary proteins (estimated MW) | |||||
|---|---|---|---|---|---|
| 12 kDa | 26 kDa | 30 kDa | 38 kDa | 44 kDa | |
| MENA | |||||
| Percentage positive sera | |||||
| Egypt | |||||
| CA (−/−) | 43.24 | 27.03 | 37.84 | 45.95 | 8.11 |
| AW (+/−) | 90.00 | 70.00 | 90.00 | 95.00 | 42.50 |
| NS (+/+) | 79.41 | 55.88 | 88.24 | 79.41 | 41.18 |
| Jordan | |||||
| AM (−/−) | 56.76 | 21.62 | 59.46 | 70.27 | 13.51 |
| MA (+/−) | 58.54 | 21.95 | 78.05 | 73.17 | 12.20 |
| SW (+/+) | 77.50 | 35.00 | 90.00 | 60.00 | 45.00 |
| Average blot intensity | |||||
| Egypt | |||||
| CA (−/−) | 0.51 ± 0.08 | 0.38 ± 0.13 | 0.62 ± 0.15 | 0.59 ± 0.12 | 0.14 ± 0.11 |
| AW (+/−) | 1.31 ± 0.15 | 0.90 ± 0.11 | 1.83 ± 0.16 | 1.33 ± 0.11 | 0.70 ± 0.12 |
| NS (+/+) | 1.26 ± 0.18 | 0.96 ± 0.17 | 2.09 ± 0.18 | 1.38 ± 0.17 | 0.84 ± 0.15 |
| Jordan | |||||
| AM (−/−) | 0.66 ± 0.10 | 0.24 ± 0.14 | 0.86 ± 0.15 | 0.97 ± 0.08 | 0.22 ± 0.11 |
| MA (+/−) | 0.76 ± 0.06 | 0.29 ± 0.15 | 1.37 ± 0.16 | 1.15 ± 0.10 | 0.13 ± 0.12 |
| SW (+/+) | 1.08 ± 0.14 | 0.41 ± 0.15 | 1.53 ± 0.15 | 0.94 ± 0.10 | 0.75 ± 0.12 |
| Immunogenicity (a.u.) | |||||
| Egypt | |||||
| CA (−/−) | 0.22 | 0.10 | 0.24 | 0.27 | 0.01 |
| AW (+/−) | 1.18 | 0.63 | 1.64 | 1.26 | 0.30 |
| NS (+/+) | 1.00 | 0.53 | 1.84 | 1.10 | 0.35 |
| Jordan | |||||
| AM (−/−) | 0.38 | 0.05 | 0.51 | 0.68 | 0.03 |
| MA (+/−) | 0.44 | 0.06 | 1.07 | 0.84 | 0.02 |
| SW (+/+) | 0.83 | 0.14 | 1.37 | 0.56 | 0.34 |
| 12 kDa | 14 kDa | 26 kDa | 30 kDa | 38 kDa | |
| US military | |||||
| Percentage positive sera | |||||
| United States | |||||
| Control | 48.28 | 51.72 | 44.83 | 48.28 | 48.28 |
| Bitten | 23.53 | 52.94 | 64.71 | 29.41 | 76.47 |
| Infected | 34.78 | 13.04 | 30.43 | 21.74 | 73.91 |
| Average blot intensity | |||||
| United States | |||||
| Control | 0.52 ± 0.57 | 0.53 ± 0.53 | 0.50 ± 0.60 | 0.64 ± 0.77 | 0.48 ± 0.51 |
| Bitten | 0.24 ± 0.44 | 0.71 ± 0.85 | 0.74 ± 0.62 | 0.29 ± 0.47 | 1.00 ± 0.71 |
| Infected | 0.52 ± 0.85 | 0.30 ± 0.82 | 0.48 ± 0.79 | 0.30 ± 0.70 | 1.70 ± 1.19 |
| Immunogenicity (arbitrary units) | |||||
| United States | |||||
| Control | 0.25 | 0.28 | 0.22 | 0.31 | 0.23 |
| Bitten | 0.06 | 0.37 | 0.48 | 0.09 | 0.76 |
| Infected | 0.18 | 0.04 | 0.15 | 0.07 | 1.25 |
Collection site abbreviations and conditional marks correspond to those abbreviations and marks presented in Table 1 (e.g., +/− refers to a region with known endemic P. papatasi populations but no reports of L. major infections or for US military personnel, donor reported history of sand fly bites but there is no confirmed diagnoses of cutaneous leishmaniasis).
Percentage of serum donors from the given location with antibody recognition of salivary proteins at the estimated MW.
Those regions with significant (P ≤ 0.05) differences in antibody reactivity compared with national negative control regions or US personnel who were not bitten by sand flies.
Western immunoblots of human sera against P. papatasi SGS were scored manually by three independent observers using a scale: 0 = no reaction; 1 = weak reaction; 2 = moderate reaction; 3 = intense reaction (all judged relative to a constant positive control).
Immunogenicity here is calculated as (probability of donor serum antibody specificity to a particular salivary protein within a regional sample group) × (average band intensity among that regional group) = a.u. of immunogenicity.
Figure 2.Immunogenicity to P. papatasi salivary gland proteins among plasma donors. (A) Immunogenicity of all P. papatasi salivary gland proteins by Egyptian blood plasma donor antibody specificities from three regions (CA, AW, and NS) using consensus estimates of MW on immunoblot images from three independent observers. (B) Immunogenicity of all P. papatasi salivary gland proteins by Jordanian blood plasma donor antibody specificities from three regions (AM, MA, and SW). Ecological conditions in the regional key are the same as those conditions outlined in Table 1. (C) Immunogenicity of all P. papatasi salivary gland proteins of Iraq-based US personnel and blood plasma donor antibody specificities from individuals differentially exposed to sand fly bites and Leishmania parasites. Exposure criteria are the same as those criteria outlined in Table 1. Immunogenicity is calculated as (probability of donor plasma antibody reaction of protein among a regional group) × (average of band intensity among that regional group) = a.u. *Significant difference(s) in host plasma antibody specificity for protein(s) at these MWs between sand fly-endemic and control regional sites or between sand fly bite-exposed military personnel and unexposed control donors (P ≤ 0.05).
Identification of majorly expressed P. papatasi salivary proteins by MS
| Unused | Sequence coverage | Accession number | Protein name | Species | No. of unique peptides | Confidence of identification | Local FDR for protein (%) | |
|---|---|---|---|---|---|---|---|---|
| 12 kDa | ||||||||
| 1 | 50.41 | 80 | gi 15963505 | 12 kDa salivary protein precursor | 56 | ∼> 1e-50 | 7e-5 | |
| 2 | 25 | 57.8 | gi 15963507 | 14 kDa salivary protein precursor | 16 | ∼> 1e-25 | 7.3e-5 | |
| 3 | 6 | 27.2 | gi 15963515 | 32 kDa salivary protein precursor | 4 | ∼> 1e-6 | 7.54e-5 | |
| 4 | 5.56 | 55.3 | gi 112497698 | 14.2 kDa salivary protein | 6 | ∼> 1e-5 | 7.66e-5 | |
| 5 | 4 | 72.1 | gi 112497317 | 13.7 kDa salivary protein | 22 | ∼> 1e-4 | 7.85e-5 | |
| 6 | 2 | 30.5 | gi 112497287 | 14.2 kDa salivary protein | 1 | 0.01 | 8.04e-5 | |
| 14 kDa | ||||||||
| 1 | 33.3 | 86.1 | gi 335954166 | SP15 protein | 50 | ∼> 1e-33 | 8.24e-5 | |
| 2 | 11.18 | 86.1 | gi 335954098 | SP15 protein | 44 | ∼> 1e-11 | 8.57e-5 | |
| 3 | 6 | 28.2 | gi 15963507 | 14 kDa salivary protein precursor | 3 | ∼> 1e-6 | 8.66e-5 | |
| 4 | 4.05 | 90.9 | gi 112497496 | 14.5 kDa salivary protein | 39 | ∼> 1e-36 | 8.76e-5 | |
| 5 | 4 | 10.6 | gi 15963515 | 32 kDa salivary protein precursor | 2 | ∼> 1e-4 | 8.86e-5 | |
| 6 | 2 | 39.4 | gi 112361953 | 14.4 kDa salivary protein | 3 | 0.01 | 9.05e-5 | |
| 7 | 2 | 32.1 | gi 157361529 | 40S ribosomal protein S12-like protein | 1 | 0.01 | 9.05e-5 | |
| 8 | 0.26 | 86.1 | gi 335954106 | SP15 protein | 40 | 0.55 | 9.55e-5 | |
| 26 kDa | ||||||||
| 1 | 30.74 | 71.3 | gi 15963511 | 28 kDa salivary protein precursor | 36 | ∼> 1e-30 | 8.78e-5 | |
| 2 | 28.47 | 70 | gi 15963513 | 30 kDa salivary protein precursor | 40 | ∼> 1e-28 | 8.85e-5 | |
| 28 kDa | ||||||||
| 1 | 30.78 | 57.5 | gi 15963511 | 28 kDa salivary protein precursor | 26 | ∼> 1e-30 | 4.69e-5 | |
| 2 | 23.26 | 60.5 | gi 15963513 | 30 kDa salivary protein precursor | 18 | ∼> 1e-23 | 4.72e-5 | |
| 30 kDa | ||||||||
| 1 | 28.72 | 56.3 | gi 76589378 | 29 kDa salivary protein precursor | 29 | ∼> 1e-28 | 9.06e-5 | |
| 2 | 12 | 37.8 | gi 15963515 | 32 kDa salivary protein precursor | 8 | ∼> 1e-12 | 9.25e-5 | |
| 38 kDa | ||||||||
| 1 | 113.02 | 92 | gi 10443907 | Salivary apyrase | 114 | ∼> 1e-113 | 4.94e-5 | |
| 2 | 6.06 | 74.1 | gi 112496715 | 35.8 kDa salivary protein | 27 | ∼> 1e-6 | 5.21e-5 | |
| 3 | 2.73 | 32 | gi 299829440 | 32.9 kDa salivary protein | 7 | ∼> 1e-3 | 5.31e-5 | |
| 40 kDa | ||||||||
| 1 | 72.21 | 80.8 | gi 15963517 | 42 kDa salivary protein precursor | 70 | ∼> 1e-72 | 5.08e-5 | |
| 2 | 9.68 | 51.1 | gi 112497236 | Yellow-related protein | 29 | ∼> 1e-9 | 5.15e-5 | |
| 3 | 7.52 | 69.1 | gi 10443907 | Salivary apyrase | 6 | ∼> 1e-72 | 5.24e-5 | |
| 42 kDa | ||||||||
| 1 | 120.09 | 89.6 | gi 15963517 | 42 kDa salivary protein precursor | 110 | ∼> 1e-120 | 1.04e-3 | |
| 2 | 21.3 | 73 | gi 15963519 | 44 kDa salivary protein precursor | 13 | ∼> 1e-21 | 1.09e-3 | |
| 3 | 15.46 | 65.6 | gi 112497236 | Yellow-related protein | 46 | ∼> 1e-15 | 1.11e-3 | |
| 4 | 4 | 55.2 | gi 299829410 | Yellow-related salivary protein | 19 | ∼> 1e-4 | 1.12e-3 | |
| 44 kDa | ||||||||
| 1 | 91.06 | 85.8 | gi 15963517 | 42 kDa salivary protein precursor | 100 | ∼> 1e-90 | 6.72e-7 | |
| 2 | 81.47 | 80.3 | gi 15963519 | 44 kDa salivary protein precursor | 97 | ∼> 1e-81 | 6.72e-7 | |
| 3 | 15.45 | 61.8 | gi 112497236 | Yellow-related protein | 49 | ∼> 1e-15 | 6.75e-7 | |
| 4 | 6.13 | 59.7 | gi 112497202 | Yellow-related protein | 41 | ∼> 1e-6 | 6.76e-7 | |
| 46 kDa | ||||||||
| 1 | 130.07 | 98.3 | gi 15963519 | 44 kDa salivary protein precursor | 188 | ∼> 1e-130 | 1.1e-5 | |
| 2 | 43.93 | 77.2 | gi 15963517 | 42 kDa salivary protein precursor | 41 | ∼> 1e-43 | 1.1e-5 | |
| 3 | 8.89 | 74.7 | gi 112497202 | Yellow-related protein | 72 | ∼> 1e-8 | 1.11e-5 | |
| 4 | 6.02 | 21.9 | gi 76446619 | Yellow-related salivary protein | 3 | ∼> 1e-6 | 1.12e-5 | |
| 5 | 4.29 | 35.1 | gi 10443907 | Salivary apyrase | 3 | ∼> 1e-4 | 1.12e-5 | |
| 6 | 2.26 | 50.1 | gi 112497236 | Yellow-related protein | 26 | ∼> 1e-3 | 1.13e-5 | |
| 7 | 2 | 38.7 | gi 52001011 | Yellow-related salivary protein | 1 | 0.01 | 1.14e-5 | |
Based on denatured protein bands excised for MS analysis (Figure 1B).
Percent representation of a protein based on unique peptide spectral assignments to that protein.
Negative log10 of the unused ProtScore, which is calculated using only peptides from spectra that have not been used by other proteins; a lower value indicates greater confidence of protein identification-based additive assignments of unique peptides.
Principle salivary proteins in K-means clusters (estimated MW)
| 12 kDa | 26 kDa | 30 kDa | 38 kDa | 44 kDa | |
|---|---|---|---|---|---|
| MENA clusters | |||||
| A | − | − | − | − | − |
| B | + | − | + | + | − |
| C | + | + | + | + | − |
| D | + | + | + | + | + |
| 12 kDa | 14 kDa | 26 kDa | 30 kDa | 38 kDa | |
| US military clusters | |||||
| E | − | − | − | − | − |
| F | − | − | − | − | + |
| G | − | + | + | + | + |
| H | + | + | − | + | − |
Cluster characteristics are defined as antibody recognition at the listed protein MW for > 50% of donors. Results details descriptions of clusters.
Figure 3.K-means clustering of total host plasma antibody specificity profiles to P. papatasi whole-salivary gland protein sonicates. Scores for human host plasma specificity to sand fly salivary proteins were separated by national and ecological region groups and then clustered by the k-means method across 1,000 iterations using Cluster v3.0, with k = 4 clusters and the Euclidean distance metric. (A) Total percentages of blood plasma donors from each Egyptian regional site assigned to each anti-SGS antibody specificity profile cluster by k-means clustering. (B) Total percentages of blood plasma donors from each Jordanian regional site assigned to each anti-SGS antibody specificity profile cluster by k-means clustering. (C) Total percentages of blood plasma donors from combined regional sites (grouped by defining ecological characteristics) (Table 1) assigned to each anti-SGS antibody specificity profile cluster by k-means clustering. (D) Total percentages of blood plasma donors from US military personnel differentially exposed to sand fly bites and Leishmania parasites assigned to each anti-SGS antibody specificity profile cluster by k-means clustering. *K-means cluster profile characteristics are outlined in Table 4. ‡A significant Pearson correlation was found between international donors from these sites.
Figure 4.Isotyping of anti-SGS human host plasma antibodies. For each k-means cluster, six plasmas most representative of that k-means cluster immunoreactivity profile and plasmas from individuals residing in each of the Middle Eastern regions were isotyped for total anti-SGS antibodies using custom indirect ELISA. Individual donor results for each antibody isotype may be found in Supplemental Figure 5. *Clusters are like those clusters described in Table 4. †Anti-SGS antibody concentrations were assessed by secondary antibody detection of a known concentration of purified Ig isotype standards, plated in dilution series as primary antigen, and fitted to the resultant standard curve; final values were averaged per cluster across all regional donors.
Figure 5.Mixed leukocyte proliferation in vitro of peripheral blood donors after stimulation of MDDCs with P. papatasi SGS. (A) Representative sampling of regional Egyptian and Jordanian resident donor cellular proliferations when exposed to SGS-stimulated autogeneic MDDCs. Proliferation was measured using coculture with tritiated thymidine for 24 hours and β-particle decay counts per minute. Values presented are ratios of stimulated over unstimulated assays normalized to a single positive control donor proliferation run concurrently. (B) Proliferation data for US military personnel differentially exposed to sand fly bites and Leishmania parasites. *Significant differences by Student's t test (P < 0.05). #Stimulation index is the ratio of β-counts (3H-thymidine uptake) between unstimulated and SGS pre-stimulated MDDCs and mixed leukocyte cocultures.
Figure 6.Secreted cytokines/chemokines of SGS-stimulated MDDCs. Culture supernatant expression of (A) IL-8, (B) IL-17, and (C) IP-10 secreted by in vitro MDDCs from differential sand fly- and Leishmania-exposed US military personnel blood donors after stimulation with SGS. *Data are MFI + SD after normalization of SGS-stimulated MDDC supernatants to paired unstimulated supernatant values. **Significant differences by Student's t test (P < 0.05).